phase readout
saveNCT05456867: A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: AstraZeneca. Phase: . Conditions: NSCLC, Non-small-cell Lung Carcinoma
view source ↗
comments(0)
5-min edit window · permanent after that